The first needle-free epinephrine nasal spray, Neffy by ARS Pharmaceuticals, represents a significant breakthrough in ...

Study exceeded target enrollment, with an expected topline data readout from the interim analysis expected in 2025 - ...

Pfizer withdrew its pill for sickle cell disease amid heightened European scrutiny, triggered by death rates seen in clinical ...

Swissmedic is expected to decide on the approval of the first new drug for Alzheimer’s disease in two decades. The decision ...

Pandemic exposed EU states to worrying pharma supply shortages, leading to widespread calls for more home-manufactured pharma ...

Britain's top brass filed into my office in No 10, bearing with them hundreds of years of collective operational experience, ...

The vaccine race: it was Brexit and Bingham what won it. There were good reasons for any member of the Tory Government to ...

Dupixent approved in the US as the first-ever biologic medicine for patients with COPD         Dupixent is indicated for the approximately 300,000 adults in the US with inadequately ...

After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...

European Union suspends Pfizer's Oxbryta for sickle cell disease due to safety concerns, urging doctors to stop use ...

Additionally, the percentage of patients reaching their LDL-C goals increased from 4.9% at pre-treatment to 35.3% at the 2Y follow-up – an approximately 7-fold increase. 1 The proportions of high-risk ...

European regulators suspended the approval of Pfizer Inc.’s sickle cell anemia drug, Oxbryta, citing a higher rate of disease ...